| Literature DB >> 35681664 |
Hou-Chuan Lai1, Yi-Wei Kuo2, Yi-Hsuan Huang1, Shun-Ming Chan1, Kuang-I Cheng2,3, Zhi-Fu Wu1,2,3,4.
Abstract
Pancreatic malignancy is a lethal neoplasm, as well as one of the leading causes of cancer-associated mortality, having a 5-year overall survival rate of less than 10%. The average life expectancy of patients with advanced pancreatic cancer does not exceed six months. Although surgical excision is a favorable modality for long-term survival of pancreatic neoplasm, metastasis is initially identified in nearly 80% of the patients by the time of diagnosis, making the development of therapeutic policy for pancreatic cancer extremely daunting. Emerging evidence shows that pancreatic neoplastic cells interact intimately with a complicated microenvironment that can foster drug resistance, metastasis, or relapse in pancreatic cancer. As a result, the necessity of gaining further insight should be focused on the pancreatic microenvironment contributing to cancer progression. Numerous evidence reveals that perioperative factors, including surgical manipulation and anesthetics (e.g., propofol, volatile anesthetics, local anesthetics, epidural anesthesia/analgesia, midazolam), analgesics (e.g., opioids, non-steroidal anti-inflammatory drugs, tramadol), and anesthetic adjuvants (such as ketamine and dexmedetomidine), might alter the tumor microenvironment and cancer progression by affecting perioperative inflammatory or immune responses during cancer surgery. Therefore, the anesthesiologist plays an important role in perioperative management and may affect surgical outcomes. However, the literature on the impact of anesthesia on the pancreatic cancer microenvironment and progression is limited. This review summarizes the current knowledge of the implications of anesthesia in the pancreatic microenvironment and provides future anesthetic strategies for improving pancreatic cancer survival rates.Entities:
Keywords: anesthesia; pancreatic cancer; tumor microenvironment
Year: 2022 PMID: 35681664 PMCID: PMC9179559 DOI: 10.3390/cancers14112684
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Anesthesia in pancreatic microenvironments.
The existing studies on the effects of anesthetics/analgesics on clinical outcomes and pancreatic microenvironments.
| Type of Anesthetics/Analgesics | Effects |
|---|---|
| Clinical studies | Propofol was associated with no or low-grade complication compared with desflurane in PC surgery [ |
| NSAIDs | In a systematic review of observational studies, there was no signification association between aspirin use and mortality risk in PC [ |
| Opioids | High opioid consumption was related to decreased survival rates in newly diagnosed stage IV PC patients [ |
| LAs | Intraoperative administration of intravenous lidocaine was associated with improvement of overall survival in PC patients [ |
| Experimental studies | Propofol attenuated malignant potential by inhibiting HIF-1α and VEGF expression [ |
| NSAIDs | Indometacin ameliorated high glucose-induced proliferation and invasion by upregulating E-cadherin (EMT) in PC cells [ |
| Opioids | Fentanyl decreased gene expression of PC stem cell markers and increased expression of apoptosis-related genes [ |
| LAs | High concentrations of ropivacaine or bupivacaine revealed antiproliferative potency in PC cells [ |
| Midazolam | Midazolam exhibited antitumor (anti-proliferation) and anti-inflammatory effects in a mouse model of PC [ |
| Ketamine | Ketamine significantly inhibited proliferation in PC cells [ |
HIF = hypoxia-inducible factor; Las = local anesthetics; MMP = matrix metalloproteinases; NSAIDs = non-steroidal anti-inflammatory drugs; PC = pancreatic cancer; Vas = volatile anesthetics; VEGF = vascular endothelial growth factor.
Figure 2A theory on the balance between recurrence/metastasis-promoting and -inhibiting factors during pancreatic cancer surgery. The strength of the promoting effect relies on the extent of the pancreatic cancer surgery, and the strength of the inhibitory effect originates in the inhibiting factors selected. (A) Propofol, local anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), ketamine, and midazolam reduce pancreatic cancer recurrence/metastasis by protecting against immunosuppression; (B) Surgical stress, inhalation anesthesia, blood transfusion, hyperglycemia, and hypothermia promote pancreatic cancer recurrence/metastasis by causing immunosuppression.